Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intracavitary Interleukin-2 (IL-2) and Lymphokine-Activated Killer (LAK) Cell Therapy for Malignant Gliomas

NCT00003067 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT00003067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intracavitary Interleukin-2 (IL-2) and Lymphokine-Activated Killer (LAK) Cell Therapy for Malignant Gliomas
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Suspended
Start date
July 31, 1997
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors